Eligo Bioscience Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 42

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $32.5M

  • Investors
  • 12

Eligo Bioscience General Information

Description

Developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine sequencing systems with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling pharmaceutical companies to make medicines from pathogen-resistant antimicrobials.

Contact Information

Website
www.eligo.bio
Formerly Known As
PhageX
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 111 Avenue De France
  • 75013 Paris
  • France

Eligo Bioscience Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eligo Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Later Stage VC (Series B) 05-Dec-2023 $32.5M 000.00 Completed Generating Revenue
9. Grant 30-Jun-2020 00.000 0000 Completed Generating Revenue
8. Grant 01-May-2019 00.000 0000 Completed Generating Revenue
7. Grant 01-Jan-2019 00.000 0000 Completed Generating Revenue
6. Early Stage VC (Series A) 26-Sep-2017 000.00 0000 000.00 Completed Generating Revenue
5. Grant 20-Sep-2016 00.000 00.000 Completed Generating Revenue
4. Early Stage VC (Series A) 01-Apr-2015 00.000 00.000 000.00 Completed Generating Revenue
3. Grant 09-Feb-2015 00000 Completed Generating Revenue
2. Accelerator/Incubator Completed Startup
1. Accelerator/Incubator Completed Startup
To view Eligo Bioscience’s complete valuation and funding history, request access »

Eligo Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
B 00,000 00.000000 000.00 000.00 00 000.00 0.000
B 000,000 00.000000 000.00 000.00 00 000.00 00.000
A 266,666 $0.047727 $8.95 $8.95 1x $8.95 11.97%
To view Eligo Bioscience’s complete cap table history, request access »

Eligo Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiot
Biotechnology
Paris, France
42 As of 2023
000.00
00000000000 000.00

000000

nsequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum d
0000 000000000
Gaithersburg, MD
00 As of 0000
000.00
000000&0 000.00

00000

, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dol
0000 000000000
Morrisville, NC
00 As of 0000
00000
00000 00000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eligo Bioscience Competitors (44)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptive Phage Therapeutics Formerly VC-backed Gaithersburg, MD 00 000.00 000000&0 000.00
Locus Biosciences Venture Capital-Backed Morrisville, NC 00 00000 00000 00000 00000
GangaGen Venture Capital-Backed Bangalore, India 00 000.00 000000 - 000 000.00
Vedanta Biosciences Venture Capital-Backed Cambridge, MA 000 00000 0000000000 0 00000
BiomX Formerly VC-backed Ness Ziona, Israel 00 000.00 000000000 000.00
You’re viewing 5 of 44 competitors. Get the full list »

Eligo Bioscience Executive Team (8)

Name Title Board Seat Contact Info
Xavier Duportet Ph.D Co-Founder, Chief Executive Officer, Directeur Général & Chairman
Aurélie Grienenberger Ph.D Chief Operating Officer, Chief Business Officer & Board Member
David Bikard Ph.D Co-Founder, Chief Technology Officer, Chief Scientific Officer & Board Member
Luciano Marraffini Ph.D Co-Founder and Advisor
Mary Spellman Chief Medical Officer
You’re viewing 5 of 8 executive team members. Get the full list »

Eligo Bioscience Board Members (7)

Name Representing Role Since
Benoit Barteau Ph.D Bpifrance Board Member 000 0000
Daniel Marhely Self Board Member 000 0000
Iain Wilcock Seventure Partners Board Member 000 0000
Jean-Pierre Lehner MD Self Board Member 000 0000
Laia Crespo-Martin Ph.D Sanofi Ventures Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Eligo Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eligo Bioscience Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sanofi Ventures Corporate Venture Capital Minority 000 0000 000000 0
CARB-X University 000 0000 000000 0
European Commission Government 000 0000 000000 0
EASME - EU Executive Agency for SMEs Corporation Minority 000 0000 000000 0
Bpifrance Sovereign Wealth Fund Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Eligo Bioscience FAQs

  • When was Eligo Bioscience founded?

    Eligo Bioscience was founded in 2014.

  • Who is the founder of Eligo Bioscience?

    Xavier Duportet Ph.D, David Bikard Ph.D, Luciano Marraffini Ph.D, and Timothy Lu MD are the founders of Eligo Bioscience.

  • Who is the CEO of Eligo Bioscience?

    Xavier Duportet Ph.D is the CEO of Eligo Bioscience.

  • Where is Eligo Bioscience headquartered?

    Eligo Bioscience is headquartered in Paris, France.

  • What is the size of Eligo Bioscience?

    Eligo Bioscience has 42 total employees.

  • What industry is Eligo Bioscience in?

    Eligo Bioscience’s primary industry is Biotechnology.

  • Is Eligo Bioscience a private or public company?

    Eligo Bioscience is a Private company.

  • What is Eligo Bioscience’s current revenue?

    The current revenue for Eligo Bioscience is 000000.

  • How much funding has Eligo Bioscience raised over time?

    Eligo Bioscience has raised $51.6M.

  • Who are Eligo Bioscience’s investors?

    Sanofi Ventures, CARB-X, European Commission, EASME - EU Executive Agency for SMEs, and Bpifrance are 5 of 12 investors who have invested in Eligo Bioscience.

  • Who are Eligo Bioscience’s competitors?

    Adaptive Phage Therapeutics, Locus Biosciences, GangaGen, Vedanta Biosciences, and BiomX are some of the 44 competitors of Eligo Bioscience.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »